Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial.

Saved in:
Bibliographic Details
Title: Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial.
Authors: Hanna MG; Medical Research Council (MRC) Centre for Neuromuscular Diseases, University College London (UCL) Institute of Neurology, London, UK. Electronic address: m.hanna@ucl.ac.uk., Badrising UA; Department of Neurology, Leiden University Medical Center, Leiden, Netherlands., Benveniste O; Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France., Lloyd TE; Department of Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, MD, USA., Needham M; Fiona Stanley Hospital, Institute for Immunology & Infectious Diseases Murdoch University and Notre Dame University, Perth, WA, Australia., Chinoy H; National Institute for Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK., Aoki M; Department of Neurology, Tohoku University School of Medicine, Sendai, Japan., Machado PM; Medical Research Council (MRC) Centre for Neuromuscular Diseases, University College London (UCL) Institute of Neurology, London, UK; Centre for Rheumatology, Division of Medicine, UCL, London, UK., Liang C; Department of Neurology, Royal North Shore Hospital, Sydney, NSW, Australia., Reardon KA; Calvary Health Care Bethlehem, Caulfield South, VIC, Australia., de Visser M; Department of Neurology, Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands., Ascherman DP; Department of Medicine, University of Miami, Miami, FL, USA., Barohn RJ; Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA., Dimachkie MM; Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA., Miller JAL; Department of Neurology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK., Kissel JT; Department of Neurology, Ohio State University Wexner Medical Center, Columbus, OH, USA., Oskarsson B; UC Davis School of Medicine, Neuromuscular Research Center, Sacramento, CA, USA., Joyce NC; UC Davis School of Medicine, Neuromuscular Research Center, Sacramento, CA, USA., Van den Bergh P; Department of Neurology, University Hospital Saint-Luc, University of Louvain, Brussels, Belgium., Baets J; Neuromuscular Reference Centre, Department of Neurology, Antwerp University Hospital, and the Institute Born-Bunge, University of Antwerp, Antwerp, Belgium., De Bleecker JL; Department of Neurology, Ghent University Hospital, Ghent, Belgium., Karam C; Department of Neurology, Oregon Health & Science University, Portland, OR, USA., David WS; Department of Neurology, Massachusetts General Hospital, Neuromuscular Diagnostic Center and Electromyography Laboratory, Boston, MA, USA., Mirabella M; Department of Neurology, Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Universitá Cattolica del Sacro Cuore, Rome, Italy., Nations SP; Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA., Jung HH; Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland., Pegoraro E; Department of Neurosciences, University of Padua School of Medicine, Padua, Italy., Maggi L; Neuroimmunology and Neuromuscular Diseases Unit, Foundation IRCCS Neurological Institute Carlo Besta, Milan, Italy., Rodolico C; Unit of Neurology and Neuromuscular Disorders, Azienda Ospedaliera Universitaria Policlinico G Martino, University of Messina, Messina, Italy., Filosto M; Center for Neuromuscular Diseases, Unit of Neurology, Azienda Socio Sanitaria Territoriale Spedali Civili and University of Brescia, Brescia, Italy., Shaibani AI; Nerve and Muscle Center of Texas, Houston, TX, USA., Sivakumar K; Neuromuscular Research Center, Phoenix, AZ, USA., Goyal NA; Department of Neurology, University of California Irvine, Amyotrophic Lateral Sclerosis & Neuromuscular Center, Orange, CA, USA., Mori-Yoshimura M; Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan., Yamashita S; Department of Neurology, Kumamoto University Hospital, Kumamoto, Japan., Suzuki N; Department of Neurology, Tohoku University Hospital, Miyagi, Japan., Katsuno M; Department of Neurology, Nagoya University Hospital, Aichi, Japan., Murata K; Wakayama Medical University Hospital, Wakayama, Japan., Nodera H; Tokushima University Hospital, Tokushima, Japan., Nishino I; Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan., Romano CD; RTI Health Solutions, Research Triangle Park, NC, USA., Williams VSL; RTI Health Solutions, Research Triangle Park, NC, USA., Vissing J; Copenhagen Neuromuscular Center, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Auberson LZ; Novartis Pharma, Basel, Switzerland., Wu M; Novartis Pharmaceuticals, East Hanover, NJ, USA., de Vera A; Novartis Pharma, Basel, Switzerland., Papanicolaou DA; Novartis Pharmaceuticals, East Hanover, NJ, USA., Amato AA; Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Corporate Authors: RESILIENT Study Group
Source: The Lancet. Neurology [Lancet Neurol] 2019 Sep; Vol. 18 (9), pp. 834-844.
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 101139309 Publication Model: Print Cited Medium: Internet ISSN: 1474-4465 (Electronic) Linking ISSN: 14744422 NLM ISO Abbreviation: Lancet Neurol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-4465
DOI:10.1016/S1474-4422(19)30200-5